KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $268000.0.

  • Arbutus Biopharma's Non-Current Assets fell 9650.31% to $268000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 8917.65%. This contributed to the annual value of $4.4 million for FY2024, which is 6451.43% down from last year.
  • As of Q3 2025, Arbutus Biopharma's Non-Current Assets stood at $268000.0, which was down 9650.31% from $148000.0 recorded in Q2 2025.
  • Arbutus Biopharma's Non-Current Assets' 5-year high stood at $64.2 million during Q1 2022, with a 5-year trough of $148000.0 in Q2 2025.
  • Its 5-year average for Non-Current Assets is $26.2 million, with a median of $17.0 million in 2023.
  • As far as peak fluctuations go, Arbutus Biopharma's Non-Current Assets skyrocketed by 62119.34% in 2022, and later crashed by 9874.82% in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Non-Current Assets stood at $43.8 million in 2021, then grew by 1.04% to $44.3 million in 2022, then tumbled by 72.06% to $12.4 million in 2023, then crashed by 64.51% to $4.4 million in 2024, then crashed by 93.9% to $268000.0 in 2025.
  • Its Non-Current Assets stands at $268000.0 for Q3 2025, versus $148000.0 for Q2 2025 and $202000.0 for Q1 2025.